MCID: ADN012
MIFTS: 47

Adenocarcinoma in Situ malady

Category: Cancer diseases

Aliases & Classifications for Adenocarcinoma in Situ

About this section

Aliases & Descriptions for Adenocarcinoma in Situ:

Name: Adenocarcinoma in Situ 10 12 65

Classifications:



External Ids:

Disease Ontology10 DOID:4943
MeSH36 D065311
SNOMED-CT59 51642000
NCIt42 C4123
UMLS65 C0334276

Summaries for Adenocarcinoma in Situ

About this section
MalaCards based summary: Adenocarcinoma in Situ is related to in situ pulmonary adenocarcinoma and cystic teratoma. An important gene associated with Adenocarcinoma in Situ is CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A), and among its related pathways are Thyroid cancer and TP53 network. Affiliated tissues include breast, cervix and prostate, and related mouse phenotypes are pigmentation and renal/urinary system.

Related Diseases for Adenocarcinoma in Situ

About this section

Diseases in the Adenocarcinoma family:

adenocarcinoma in situ

Diseases related to Adenocarcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 144)
idRelated DiseaseScoreTop Affiliating Genes
1in situ pulmonary adenocarcinoma32.3CDX2, KRAS, KRT20
2cystic teratoma30.4CDX2, KRT20
3adenocarcinoma10.8
4nervous system benign neoplasm10.7CDX2, KRT20
5paget's disease of bone10.7CDX2, KRT20
6extrahepatic bile duct cystadenoma10.7CDX2, KRT20
7duodenum adenoma10.7CDX2, KRT20
8ovarian cancer10.7CDX2, KRT20
9nodular tenosynovitis10.7CDX2, KRT20
10ovarian germ cell teratoma10.7KRAS, KRT20
11appendix mucinous cystadenocarcinoma10.7CDX2, KRT20
12sweat gland cancer10.7CDKN2A, KRAS
13ovary adenocarcinoma10.7CDX2, KRT20
14gastrointestinal carcinoma10.7CDKN2A, KRAS
15intracranial sinus thrombosis10.7CDX2, KRAS
16benign mesenchymoma10.7CDKN2A, KRAS
17vulvar alveolar soft part sarcoma10.6CDKN2A, KRT20
18heart septal defect10.6CDX2, KRT20
19basophilic carcinoma10.6CDKN2A, CDX2
20bronchiolo-alveolar adenocarcinoma10.6CDX2, KRT20
21lutembacher's syndrome10.6CDX2, KRT20
22malignant giant cell tumor of soft parts10.6KRAS, KRT20
23vulva adenocarcinoma10.6CDKN2A, KRT20
24heel spur10.6CDKN2A, KRT20
25serous surface papilloma10.6KRAS, KRT20
26ovarian cystadenoma10.6CDX2, KRT20
27peptic ulcer perforation10.6CDKN2A, PAX8
28allergic contact dermatitis10.6CDX2, KRT20
29mucinous stomach adenocarcinoma10.6KRAS, KRT20
30gastrointestinal neuroendocrine tumor10.6CDKN2A, CDX2
31pancreatic foamy gland adenocarcinoma10.6CDX2, KRT20
32bile duct signet ring cell carcinoma10.6CDX2, KRT20
33rectum mucinous adenocarcinoma10.6CDKN2A, PAX2
34head and neck carcinoma10.6KRAS, KRT20
35stone in bladder diverticulum10.6CDX2, KRT20
36central nervous system endodermal sinus tumor10.6PAX2, PAX8
37acinar cell carcinoma10.5KRT20, PAX2
38breast mucinous cystadenocarcinoma10.5CDX2, KRT20
39cervicitis10.5
40pediatric ovarian dysgerminoma10.5PAX2, PAX8
41ovary neuroendocrine neoplasm10.5KRAS, WT1
42muscle tissue disease10.5CDX2, KRT20
43anal neuroendocrine tumor10.5CDKN2A, WT1
44lung combined large cell neuroendocrine carcinoma10.5CDKN2A, WT1
45acute pancreatitis10.5CDKN2A, PAX8
46nasal cavity adenocarcinoma10.5CDX2, KRT20
47gastrointestinal system cancer10.5PAX2, PAX8
48breast mucinous carcinoma10.5MCM2, PAX2
49aortitis10.5CDX2, WT1
50urethra adenocarcinoma10.5KRT20, WT1

Graphical network of the top 20 diseases related to Adenocarcinoma in Situ:



Diseases related to adenocarcinoma in situ

Symptoms for Adenocarcinoma in Situ

About this section

Drugs & Therapeutics for Adenocarcinoma in Situ

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)15 Company Approval Date
1
Cervarix15 41 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
FDA Label: -
Disease/s that Drug Treats:prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18
Indications and Usage:15 -
DrugBank Targets: -
Mechanism of Action:15 
Target: IgG neutralizing antibodies directed against HPV-L1 capsid proteins
Action: activates/ provokes production
FDA: -
2
Gardasil15 41 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
FDA Label: Gardasil
Disease/s that Drug Treats:Cervical Cancer Caused by Human Papillomavirus
Indications and Usage:15 GARDASIL is a vaccine indicated in girls and women 9 through 26years of age for the prevention of the following diseases caused byHuman Papillomavirus (HPV) types included in the vaccine: Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16and 18 (1.1) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.1)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervicaladenocarcinoma in situ (AIS) (1.1) Cervical intraepithelial neoplasia (CIN) grade 1 (1.1) Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 (1.1) Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 (1.1) Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 (1.1)GARDASIL is indicated in boys and men 9 through 26 years of age forthe prevention of the following diseases caused by HPV types includedin the vaccine: Anal cancer caused by HPV types 16 and 18 (1.2) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.2)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.2)Limitations of GARDASIL Use and Effectiveness: GARDASIL does not eliminate the necessity for women tocontinue to undergo recommended cervical cancer screening.(1.3, 17) Recipients of GARDASIL should not discontinue anal cancerscreening if it has been recommended by a health care provider.(1.3, 17) GARDASIL has not been demonstrated to provide protectionagainst disease from vaccine and non-vaccine HPV types to whicha person has previously been exposed through sexual activity.(1.3, 14.4, 14.5) GARDASIL is not intended to be used for treatment of activeexternal genital lesions; cervical, vulvar, vaginal, and analcancers; CIN; VIN; VaIN, or AIN. (1.3) GARDASIL has not been demonstrated to protect againstdiseases due to HPV types not contained in the vaccine. (1.3,14.4, 14.5) Not all vulvar, vaginal, and anal cancers are caused by HPV, andGARDASIL protects only against those vulvar, vaginal, and analcancers caused by HPV 16 and 18. (1.3) GARDASIL does not protect against genital diseases not causedby HPV. (1.3) Vaccination with GARDASIL may not result in protection in allvaccine recipients. (1.3) GARDASIL has not been demonstrated to prevent HPV-relatedCIN 2/3 or worse in women older than 26 years of age. (14.7)
DrugBank Targets: -
Mechanism of Action:15 
Target: humoral immune response
Action: inducer
FDA: HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest thatthe efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Humanbeings develop a humoral immune response to the vaccine, although the exact mechanism of protectionis unknown.

Drugs for Adenocarcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 170)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1VaccinesPhase 4, Phase 3, Phase 2, Phase 16085
2
Oxaliplatinapproved, investigationalPhase 2, Phase 3, Phase 1132261825-94-35310940, 9887054, 6857599, 43805, 6857599, 9887054
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
 
Oxalatoplatin
Oxalatoplatinum
Oxaliplatin
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
3
leucovorinapprovedPhase 2, Phase 3, Phase 19521492-18-854575
Synonyms:
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid
(6S)-Folinic acid
(6S)-Leucovorin
(S)-Leucovorin
Calcium citrovorum factor
Calcium folinate
Citrovorum factor
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid-SF
Fusilev
 
L-Folinic acid
L-leucovorin
Leucal
Leucovorin
Leucovorin Calcium
Leucovorin calcium
Leucovorin folinic acid
Leucovorin sodium
Leukovorin
Levofolene
Levofolinic acid
Levoleucovorin
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid
Wellcovorin
4
Letrozoleapproved, investigationalPhase 3, Phase 2, Phase 1358112809-51-53902
Synonyms:
1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole
1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole
112809-51-5
4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile
4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile)
4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole
4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile
4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
AB00514009
AC-1193
AC1L1GYT
AKOS005145822
BIDD:GT0015
BIDD:PXR0130
BPBio1_001331
BRD-K88789588-001-03-2
BSPBio_001209
Bio-0057
C067431
C08163
C17H11N5
CAS-112809-51-5
CCRIS 8822
CGS 20267
CGS 20267, Femara, Piroxicam, Letrozole
CGS-20267
CHEBI:6413
CHEMBL1444
CID3902
CPD000466343
D00964
 
DB01006
FEM-345
Femara
Femara (TN)
Femera
HMS1571M11
HMS2051E08
HMS2089L22
HSDB 7461
I06-0022
LS-38788
Letoval
Letrozol
Letrozole
Letrozole (JAN/USP/INN)
Letrozole [USAN:INN]
MLS000759455
MLS001424038
MLS002584991
MolPort-003-848-373
NCGC00016973-01
NCGC00016973-02
NSC719345
Novartis Brand of Letrozole
Prestwick0_001025
Prestwick1_001025
Prestwick2_001025
Prestwick3_001025
S1235_Selleck
SAM001246649
SMR000466343
SPBio_003070
TL8000371
UNII-7LKK855W8I
ZINC03778874
letrozole
5
Capecitabineapproved, investigationalPhase 3, Phase 21220154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
6
Fentanylapproved, illicit, investigationalPhase 3705437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Abstral
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl - Novaplus
Fentanyl Citrate
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Lazanda
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Subsys
UNII-UF599785JZ
fentanyl
7
Irinotecanapproved, investigationalPhase 2, Phase 3, Phase 1104497682-44-5, 100286-90-660838
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
97682-44-5
AC-7469
AC1L1U0Z
AC1Q6PGI
BRD-K08547377-003-02-4
BSPBio_002346
Bio-0054
Biotecan
Biotecan (TN)
C16641
C33H38N4O6
CHEBI:105985
CHEMBL481
CID60838
CP0
Campothecin-11
Campto
Camptosar
 
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
D08086
DB00762
FT-0083650
HSDB 7607
IRINOTECAN HYDROCHLORIDE Trihydrate
IRINOTECAN, CPT-11
Irinotecan
Irinotecan (INN)
Irinotecan Hcl
Irinotecan Hydrochloride
Irinotecan Hydrochloride Trihydrate
Irinotecan [INN:BAN]
Irinotecan hydrochloride
Irinotecanum
Irinotecanum [INN-Latin]
LS-44589
NCI60_005051
NSC728073
S1198_Selleck
TL8006026
UNII-7673326042
irinotecan
8
TamoxifenapprovedPhase 3, Phase 235010540-29-12733526
Synonyms:
(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC)
(Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE
(Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
,citrate
1-P-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
10540-29-1
1ya4
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
54965-24-1 (citrate)
AC1MBZ3R
Apo-Tamox
Apo-tamox
BIDD:ER0008
BIDD:GT0009
BIDD:PXR0003
BPBio1_000278
BRD-K93754473-001-02-9
BRD-K93754473-048-05-3
BSPBio_000252
BSPBio_001150
BSPBio_001982
C07108
C26H29NO
CCRIS 3275
CHEBI:41774
CHEMBL83
CID2733526
Citofen
Crisafeno
D08559
DB00675
Diemon
EINECS 234-118-0
Gen-Tamoxifen
Gen-tamoxifen
HMS1362J11
HMS1792J11
HMS1990J11
HMS2090N08
HSDB 6782
ICI 47699
ICI-46,474
ICI-47699
IDI1_000258
IDI1_002170
Istubol
Kessar
L024126
LS-393
Lopac0_001203
MLS001332535
MLS001332536
MolPort-003-850-384
 
NCGC00024928-01
NCGC00024928-03
NCGC00024928-04
NCGC00024928-05
NCGC00024928-07
NCGC00024928-08
NCGC00024928-09
NCGC00024928-12
NSC727681
Noltam
Nolvadex
Nolvadex-D
Nourytam
Novaldex
Novo-Tamoxifen
Oncomox
PMS-Tamoxifen
Pms-Tamoxifen
Prestwick2_000146
Prestwick3_000146
QTL1_000079
Retaxim
SMR000059172
ST50511785
Soltamox
Spectrum5_001417
Spectrum5_002043
T5648_SIGMA
TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1))
TRANS FORM OF TAMOXIFEN
Tamizam
Tamofen
Tamone
Tamoplex (TN)
Tamoxasta
Tamoxen
Tamoxifen
Tamoxifen (INN)
Tamoxifen (TN)
Tamoxifen (Z)
Tamoxifen Citrate
Tamoxifen [INN:BAN]
Tamoxifen and its salts
Tamoxifene
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tamoxifène
Tocris-0999
Tomaxithen
Trans-Tamoxifen
UNII-094ZI81Y45
UPCMLD-DP027
Valodex
Zemide
cMAP_000044
nchembio.140-comp7
nchembio.76-comp1
nchembio732-comp3
tamoxifen
trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
trans-Tamoxifen
9
Trastuzumabapproved, investigationalPhase 3, Phase 2726180288-69-19903
Synonyms:
180288-69-1
Anti HER2
Anti-erbB2 Monoclonal Antibody
D03257
HER2 Monoclonal Antibody
Herceptin
 
Herceptin (TN)
Ig gamma-1 chain C region
Trastuzumab
Trastuzumab (INN)
Trastuzumab (genetical recombination)
Trastuzumab (genetical recombination) (JAN)
trastuzumab
10
Bevacizumabapproved, investigationalPhase 2, Phase 31875216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
11
CetuximabapprovedPhase 2, Phase 3, Phase 1713205923-56-456842117, 2333
Synonyms:
205923-56-4
Anti EGFR
Cetuximab
Cetuximab (USAN/INN)
Cetuximab (genetical recombination)
 
Cetuximab (genetical recombination) (JAN)
D03455
Erbitux
Erbitux (TN)
IMC-C225
cetuximab
12
FluorouracilapprovedPhase 2, Phase 3, Phase 1168451-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
13
Anastrozoleapproved, investigationalPhase 3, Phase 2262120511-73-12187
Synonyms:
.alpha.,alpha.,.alpha.',.alpha.'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
1,3-benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)
120511-73-1
2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile)
2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
AC-4234
AC1L1D49
Anastrazole
Anastrole
Anastrozol
Anastrozole
Anastrozole (JAN/USAN/INN)
Anastrozole [USAN:INN:BAN]
Arimidex
Arimidex (TN)
Arimidex (Zeneca)
Arimidex, Anastrozole
Asiolex
Astra brand of anastrozole
AstraZeneca brand of anastrozole
C08159
C090450
C17H19N5
CHEBI:2704
CHEMBL1399
CID2187
CPD000466301
 
D00960
DB01217
HMS2052M11
HMS2089N10
HSDB 7462
I06-0021
ICI D1033
ICI-D 1033
ICI-D1033
LS-29563
MLS000759396
MLS001424217
MolPort-005-933-078
NCGC00164619-01
NSC719344
S1188_Selleck
SAM001246525
SBB066057
SMR000466301
UNII-2Z07MYW1AZ
ZD 1033
ZD-1033
ZD1033
ZINC00000941
Zeneca ZD 1033
Zeneca brand of anastrozole
alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
anastrazole
anastrozole
14
EpirubicinapprovedPhase 3, Phase 236156420-45-241867
Synonyms:
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione
4'-Epi-DXR
4'-Epiadriamycin
4'-Epidoxorubicin
4'-epi-DX
4'-epi-Doxorubicin
4'-epidoxorubicin
4-Epidoxorubicin
56390-09-1
56390-09-1 (hydrochloride)
56420-45-2
57918-25-9
AC1L26NP
AC1Q6JIV
BRN 1445813
C11230
C27H29NO11
CCRIS 2261
CHEBI:47898
CHEMBL417
CID41867
D07901
DB00445
Ellence
Epi-DX
Epi-Dx
Epiadriamycin
Epidoxorubicin
Epirubicin
 
Epirubicin (INN)
Epirubicin [INN:BAN]
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin (TN)
HSDB 6962
IMI 28
LS-187190
LS-93992
MLS000759412
NChemBio.2007.10-comp15
NSC 256942
NSC-256942
NSC256942
Pharmorubicin Pfs
Pidorubicin
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
SMR000466308
Triferric doxorubicin
UNII-3Z8479ZZ5X
WP 697
15
MetforminapprovedPhase 31645657-24-9, 1115-70-414219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMBG
DMGG
Diabefagos
Diabetosan
Diabex
Diaformin
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Meguan
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin Hydrochloride
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
Obimet
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
16
Exemestaneapproved, investigationalPhase 3197107868-30-460198
Synonyms:
(8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione
107868-30-4
6-Methylenandrosta-1,4-diene-3,17-dione
6-Methyleneandrosta-1,4-diene-3,17-dione
6-methylideneandrosta-1,4-diene-3,17-dione
AC-2171
AC1L1SRB
AC1Q6AAZ
Ambap107868-30-4
Aromasil
Aromasin
Aromasin (TN)
Aromasin, Exemestane
Aromasine
C056516
C08162
CHEBI:4953
CHEMBL1200374
CID60198
CPD000466314
Curator_000009
D00963
DB00990
EXE
EXEMESTANE
 
Exemestance
Exemestane
Exemestane (JAN/USP/INN)
Exemestane [USAN:INN:BAN]
Exemestano
Exemestano [INN-Spanish]
Exemestanum
Exemestanum [INN-Latin]
FCE-24304
Fce 24304
HMS2051J04
HSDB 7463
LS-19329
MLS000759419
MLS001424062
MolPort-003-847-343
NSC713563
Nikidess
PNU-155971
Pfizer brand of exemestane
S1196_Selleck
S1196_Sellek
SAM001246574
SMR000466314
UNII-NY22HMQ4BX
ZINC03973334
exemestane
17Antineoplastic Agents, HormonalPhase 3, Phase 24256
18Aromatase InhibitorsPhase 3, Phase 2, Phase 1721
19Nucleic Acid Synthesis InhibitorsPhase 3, Phase 23836
20Bone Density Conservation AgentsPhase 3, Phase 22600
21Antibiotics, AntitubercularPhase 3, Phase 25971
22Anti-Infective AgentsPhase 3, Phase 2, Phase 117220
23Pharmaceutical SolutionsPhase 3, Phase 27004
24HormonesPhase 3, Phase 2, Phase 1, Phase 011748
25Selective Estrogen Receptor ModulatorsPhase 3, Phase 2501
26AntibodiesPhase 3, Phase 1, Phase 24477
27Antibodies, MonoclonalPhase 3, Phase 1, Phase 22413
28ImmunoglobulinsPhase 3, Phase 1, Phase 24477
29Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 3, Phase 2, Phase 1, Phase 09988
30Alkylating AgentsPhase 3, Phase 2, Phase 13582
31Estrogen Receptor ModulatorsPhase 3, Phase 2544
32EstrogensPhase 3, Phase 2, Phase 12144
33Hormone AntagonistsPhase 3, Phase 2, Phase 1, Phase 010002
34Estrogen AntagonistsPhase 3, Phase 2, Phase 11155
35Anti-Bacterial AgentsPhase 3, Phase 29140
36Antimetabolites, AntineoplasticPhase 3, Phase 2, Phase 15770
37AntimetabolitesPhase 3, Phase 2, Phase 19454
38Immunosuppressive AgentsPhase 3, Phase 2, Phase 110422
39AnalgesicsPhase 3, Phase 1, Phase 29358
40AnestheticsPhase 37385
41Topoisomerase InhibitorsPhase 2, Phase 3, Phase 14081
42topoisomerase I inhibitorsPhase 2, Phase 3, Phase 11131
43Antineoplastic Agents, PhytogenicPhase 2, Phase 3, Phase 14294
44Immunologic FactorsPhase 3, Phase 2, Phase 118483
45Calcium, DietaryPhase 2, Phase 3, Phase 14678
46LevoleucovorinPhase 2, Phase 3, Phase 1676
47Protective AgentsPhase 2, Phase 3, Phase 15651
48Anesthetics, GeneralPhase 32274
49Analgesics, OpioidPhase 32304
50NarcoticsPhase 3, Phase 22709

Interventional clinical trials:

(show top 50)    (show all 158)
idNameStatusNCT IDPhase
1Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®CompletedNCT01448447Phase 4
2Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast CancerCompletedNCT00742222Phase 4
3Safety and Efficacy Study of the Xoft® Axxent® eBx™ IORT SystemRecruitingNCT01644669Phase 4
4V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)Active, not recruitingNCT01544478Phase 4
5Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)CompletedNCT00092521Phase 3
6Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy ParticipantsCompletedNCT00128661Phase 3
7A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501) in Women (V501-019)CompletedNCT00090220Phase 3
8Efficiency of Two Dimensional High Definition Versus Three Dimensional Endoscopic Systems in Transanal Endoscopic SurgeryCompletedNCT01498354Phase 3
9Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal CancerCompletedNCT00975897Phase 2, Phase 3
10Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by SurgeryCompletedNCT00647530Phase 3
11Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
12Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast CancerCompletedNCT01112254Phase 3
13Intraoperative Gamma Camera for Breast Cancer SurgeryCompletedNCT00757302Phase 3
14Study of Ablation for the Pulmonary Focal Pure Ground Glass Opacity (pGGO)RecruitingNCT01429649Phase 3
15Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast CancerRecruitingNCT01905046Phase 3
16Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder CancerRecruitingNCT01094964Phase 3
17Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast CancerRecruitingNCT01272037Phase 3
18Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing CoordinatorActive, not recruitingNCT00321048Phase 3
19Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone LumpectomyActive, not recruitingNCT00769379Phase 3
20Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation TherapyActive, not recruitingNCT00053898Phase 3
21Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the BreastActive, not recruitingNCT00470236Phase 3
22Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With MicroinvasionNot yet recruitingNCT02011997Phase 3
23Breast Cancer WEight Loss Study (BWEL Study)Not yet recruitingNCT02750826Phase 3
24Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)CompletedNCT00365716Phase 2
25Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal CancerCompletedNCT00551421Phase 1, Phase 2
26Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast CancerCompletedNCT00054301Phase 2
27Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal CancerCompletedNCT00655499Phase 2
28Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal CancerCompletedNCT00281736Phase 2
29Phase II Study of Irinotecan and PanitumumabCompletedNCT00836277Phase 2
30Endoscopic Therapy of Early Cancer in Barretts EsophagusCompletedNCT00217087Phase 2
314-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in SituCompletedNCT00952731Phase 2
32Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast CancerCompletedNCT00416403Phase 2
33MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-SituCompletedNCT00586326Phase 2
34Breast Cancer Chemoprevention by SOM230, an IGF-I Action InhibitorCompletedNCT01372618Phase 2
35Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal SymptomsCompletedNCT01194440Phase 2
36Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney TumorsCompletedNCT00335556Phase 2
37Use of N-Acetylcysteine During Liver ProcurementCompletedNCT01394497Phase 2
38Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast CancerRecruitingNCT02515110Phase 2
39Study of a Recombinant Adenovirus to Treat Localized Prostate CancerRecruitingNCT01931046Phase 1, Phase 2
40Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)RecruitingNCT00669747Phase 2
41Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)RecruitingNCT01023477Phase 1, Phase 2
42Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in SituRecruitingNCT01439711Phase 2
43Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast CancerRecruitingNCT02137252Phase 2
44Partial Breast Irradiation for Low-risk Ductal Carcinoma In Situ After Breast-conserving SurgeryRecruitingNCT02617082Phase 2
45Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing MastectomyRecruitingNCT02314156Phase 2
46Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast CancerRecruitingNCT01869764Phase 2
47PK Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing MastectomyRecruitingNCT02540330Phase 2
48Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After SurgeryRecruitingNCT02526498Phase 2
49"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"RecruitingNCT01641406Phase 2
50Single Fraction Intraoperative RadiotherapyRecruitingNCT01688388Phase 1, Phase 2

Search NIH Clinical Center for Adenocarcinoma in Situ

Genetic Tests for Adenocarcinoma in Situ

About this section

Anatomical Context for Adenocarcinoma in Situ

About this section

MalaCards organs/tissues related to Adenocarcinoma in Situ:

33
Breast, Cervix, Prostate, Lung, Testes, Liver, Colon

Animal Models for Adenocarcinoma in Situ or affiliated genes

About this section

MGI Mouse Phenotypes related to Adenocarcinoma in Situ:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.4CDKN2A, KRAS, MCM2, PAX2
2MP:00053678.5CDKN1A, KRAS, PAX2, PAX8, WT1
3MP:00020068.4CDKN1A, CDKN2A, CDX2, KRAS, MCM2, WT1
4MP:00053898.0CDKN1A, CDKN2A, CDX2, KRAS, PAX2, PAX8
5MP:00053857.7CDKN1A, CDKN2A, CDX2, KRAS, PAX2, PAX8
6MP:00053807.6CDKN1A, CDKN2A, CDX2, KRAS, MCM2, PAX2
7MP:00053797.6CDKN1A, CDKN2A, CDX2, KRAS, MCM2, PAX2
8MP:00053847.4CDKN1A, CDKN2A, CDX2, KRAS, MCM2, PAX2
9MP:00053786.8CDKN1A, CDKN2A, CDX2, CLDN1, KRAS, MCM2
10MP:00107686.5CDKN1A, CDKN2A, CDX2, CLDN1, KRAS, MCM2

Publications for Adenocarcinoma in Situ

About this section

Articles related to Adenocarcinoma in Situ:

(show top 50)    (show all 245)
idTitleAuthorsYear
1
Diagnosis of lung adenocarcinoma in situ and minimally invasive adenocarcinoma from intraoperative frozen sections: an analysis of 136 cases. (27174927)
2016
2
The effect of coexisting squamous cell lesions on prognosis in patients with cervical adenocarcinoma in situ. (25956340)
2015
3
Cytological variations and typical diagnostic features of endocervical adenocarcinoma in situ: A retrospective study of 74 cases. (25972909)
2015
4
Management of Adenocarcinoma In Situ of the Uterine Cervix: A Comparison of Loop Electrosurgical Excision Procedure and Cold Knife Conization. (25089550)
2014
5
Diagnosis of metachronous multiple lung adenocarcinoma at the cut-end by epidermal growth factor receptor mutation status discordance 4A years after sublobar resection for adenocarcinoma in situ: report of a case. (25377270)
2014
6
High pathologic misdiagnosis of cervical adenocarcinoma in situ. (24475580)
2013
7
Risk of residual disease and invasive carcinoma in women treated for adenocarcinoma in situ of the cervix. (23541795)
2013
8
Factors predicting the outcome of conservatively treated adenocarcinoma in situ of the uterine cervix: an analysis of 166 cases. (22188786)
2012
9
Fertility-sparing treatment in younger women with adenocarcinoma in situ of the cervix. (22030403)
2012
10
Predictive value of negative cone margin status for risk of residual disease among women with cervical adenocarcinoma in situ. (22939281)
2012
11
Using multi-detector-row CT to diagnose ampullary adenoma or adenocarcinoma in situ. (21093190)
2011
12
Cervical adenocarcinoma in situ with negative conization margin: negligible or not? (21607088)
2011
13
Pagetoid adenocarcinoma in situ of the cervix with pagetoid spread into the vagina. (21768854)
2011
14
Risk for residual adenocarcinoma in situ or cervical adenocarcinoma in women undergoing loop electrosurgical excision procedure/conization for adenocarcinoma in situ. (22010519)
2011
15
Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. (20423964)
2010
16
Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases. (20414103)
2010
17
Simultaneous squamous cell carcinoma in situ and adenocarcinoma in situ of the uterine cervix in a 36-year-old Japanese woman. (19693522)
2010
18
A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics. (19188825)
2009
19
Management of atypical glandular cells and adenocarcinoma in situ. (19061821)
2008
20
Significant decrease of adenocarcinoma in situ not reflected in cervical adenocarcinoma incidence in the Netherlands 1989-2003. (18182979)
2008
21
Low p53 and retinoblastoma protein expression in cervical intraepithelial neoplasia grade 3 lesions is associated with coexistent adenocarcinoma in situ. (18234283)
2008
22
IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. (17192788)
2007
23
Variants of human papillomavirus types 16 and 18: histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in cervical smear. (16990718)
2006
24
Can adenocarcinoma in situ of the uterine cervix be predicted before cervical conization? (17250421)
2006
25
Is improved detection of adenocarcinoma in situ by screening a key to reducing the incidence of cervical adenocarcinoma? (15471248)
2004
26
Postconization surveillance of cervical adenocarcinoma in situ. A prospective trial. (14619639)
2003
27
Endocervical curettage at conization to predict residual cervical adenocarcinoma in situ. (12468353)
2002
28
Adenocarcinoma in situ of the cervix-controversies in diagnosis and treatment. (17043583)
2001
29
Conservative management of adenocarcinoma in situ of the cervix. (17043589)
2001
30
Atypical glandular cells of undetermined significance in cervical smears after conization. Cytologic features differentiating them from adenocarcinoma in situ. (11284300)
2001
31
Vaginal adenosis with adenocarcinoma in situ in a woman with no recognised antecedent factors. (11284657)
2001
32
Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. (11303584)
2001
33
Adenocarcinoma in situ with a small cell (endometrioid) pattern in cervical smears: a test of the distinction from benign mimics using specific criteria. (10536349)
1999
34
Adenocarcinoma in situ of the cervix: management and outcome. (10366458)
1999
35
Abnormal expression of sex steroid receptors and cell cycle-related molecules in adenocarcinoma in situ of the uterine cervix. (10202666)
1999
36
Comparison of ThinPrep and Pap smear in relation to prediction of adenocarcinoma in situ. (9987454)
1999
37
Adenocarcinoma in situ in Barrett's esophagus with stricture of 10-yr duration: a cytological diagnosis. (8759681)
1996
38
Adenocarcinoma in situ of the cervix: significance of cone biopsy margins. (8684768)
1996
39
Atypical glandular cells of undetermined significance and adenocarcinoma in situ: summoning colposcopic expertise? (8708629)
1996
40
Small-cell neuroendocrine carcinoma of the uterine cervix associated with micro-invasive squamous cell carcinoma and adenocarcinoma in situ. (8870009)
1996
41
Management and follow-up of patients with adenocarcinoma in situ of the uterine cervix. (7729727)
1995
42
Adenocarcinoma in situ of the endocervix: human papillomavirus determination by dot blot hybridization and polymerase chain reaction amplification. (8005736)
1994
43
Colposcopy of adenocarcinoma in situ and invasive adenocarcinoma of the cervix. (8332305)
1993
44
The topography and invasive potential of cervical adenocarcinoma in situ, with and without associated squamous dysplasia. (2298414)
1990
45
Cervical adenocarcinoma in situ. (3285263)
1988
46
The cytologic diagnosis of adenocarcinoma in situ of the cervix uteri and related lesions. III. Pitfalls in diagnosis. (3376699)
1988
47
A retrospective review of adenocarcinoma-in-situ and glandular atypia of the uterine cervix. (3040074)
1987
48
Papillary adenocarcinoma in situ of bladder. (4032558)
1985
49
The cytologic diagnosis of adenocarcinoma in situ of the cervix uteri. (266347)
1977
50
Simultaneous adenocarcinoma in situ and epidermoid carcinoma in situ. Report of two cases. (6073902)
1967

Variations for Adenocarcinoma in Situ

About this section

Expression for genes affiliated with Adenocarcinoma in Situ

About this section
Search GEO for disease gene expression data for Adenocarcinoma in Situ.

Pathways for genes affiliated with Adenocarcinoma in Situ

About this section

GO Terms for genes affiliated with Adenocarcinoma in Situ

About this section

Biological processes related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

(show all 20)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of metanephric DCT cell differentiationGO:200059410.4PAX2, PAX8
2negative regulation of apoptotic process involved in metanephric collecting duct developmentGO:190021510.3PAX2, PAX8
3pronephric field specificationGO:003900310.3PAX2, PAX8
4positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesisGO:007210810.3PAX2, PAX8
5metanephric distal convoluted tubule developmentGO:007222110.3PAX2, PAX8
6negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesisGO:007230510.3PAX2, PAX8
7positive regulation of branching involved in ureteric bud morphogenesisGO:009019010.3PAX2, PAX8
8mesenchymal to epithelial transition involved in metanephros morphogenesisGO:000333710.3PAX2, PAX8
9metanephric S-shaped body morphogenesisGO:007228410.2PAX8, WT1
10urogenital system developmentGO:000165510.2PAX2, PAX8
11cellular response to gonadotropin stimulusGO:007137110.1PAX8, WT1
12negative regulation of cyclin-dependent protein serine/threonine kinase activityGO:004573610.0CDKN1A, CDKN2A
13metanephric mesenchyme developmentGO:007207510.0PAX2, WT1
14camera-type eye developmentGO:004301010.0PAX2, WT1
15inner ear morphogenesisGO:00424729.9PAX2, PAX8
16negative regulation of phosphorylationGO:00423269.8CDKN1A, CDKN2A
17metanephric epithelium developmentGO:00722079.6PAX2, PAX8, WT1
18replicative senescenceGO:00903999.6CDKN1A, CDKN2A
19positive regulation of transcription, DNA-templatedGO:00458939.2CDKN2A, CDX2, PAX8, WT1
20regulation of transcription, DNA-templatedGO:00063558.8CDX2, PAX2, PAX8, WT1

Sources for Adenocarcinoma in Situ

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet